SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENTAnd Manufacturing Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENT (“Second Amendment”) is made and entered into this 27th day of February, 2013 (“Second Amendment Effective Date”) by and between BAXTER HEALTHCARE CORPORATION, a Delaware corporation (“Baxter”), and CORNERSTONE THERAPEUTICS, a Delaware corporation (“Cornerstone”).
THE USE OF THE FOLLOWING NOTATION IN THIS EXHIBIT INDICATES THAT THE CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION:...And Manufacturing Agreement • March 13th, 2020 • Gogo Inc. • Communications services, nec
This is Amendment No. 1 (the “Amendment”), dated as of the Effective Date in the signature block, to the Amended and Restated Product Development and Manufacturing Agreement dated April 1, 2016 (the “Agreement”), and is by and between Gogo LLC (“Gogo”) and ThinKom Solutions, Inc. (ThinKom”). Gogo and ThinKom are each referred to hereinafter as a “Party” or collectively as the “Parties”.
THE USE OF THE FOLLOWING NOTATION IN THIS EXHIBIT INDICATES THAT THE CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION:...And Manufacturing Agreement • August 6th, 2015 • Gogo Inc. • Communications services, nec
This amendment (“Amendment No. 2”) is the second amendment to the November 14, 2012 Product Development and Manufacturing Agreement, as amended by the first amendment dated June 10, 2014 (collectively, the “Agreement”) and related Exhibits between ThinKom Solutions, Inc. (“ThinKom”) and Gogo LLC (“Gogo”). This Amendment No. 2 is effective as of January 31, 2015. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
CLINICAL DEVELOPMENT AND MANUFACTURING AGREEMENT BETWEEN BIOGEN INC. AND VIR BIOTECHNOLOGY, INC. DATED May 22, 2020And Manufacturing Agreement • June 23rd, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Clinical Development and Manufacturing Agreement (“Agreement”) is made as of this 22nd day of May, 2020 (“Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation, having a place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”) and Biogen Inc., a Delaware corporation, having a place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”).
THE USE OF THE FOLLOWING NOTATION IN THIS EXHIBIT INDICATES THAT THE CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION:...And Manufacturing Agreement • August 6th, 2015 • Gogo Inc. • Communications services, nec
This amendment (“Amendment No. l”) is the first amendment to the November 14, 2012 Product Development and Manufacturing Agreement (the “Agreement”) and related Exhibits between ThinKom Solutions, Inc. (“ThinKom”) and Gogo LLC (“Gogo”). This Amendment No. 1 is effective as of June 10, 2014. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
